# Scleroderma myocarditis with severe secondary mitral regurgitation successfully treated with transcatheter edge-to-edge repair: a case report

## TL;DR

A patient with scleroderma myocarditis and severe heart failure was successfully treated with a minimally invasive mitral valve repair procedure.

## Contribution

This is the first reported case of mitral transcatheter edge-to-edge repair used to treat severe ventricular functional mitral regurgitation caused by scleroderma myocarditis.

## Key findings

- M-TEER significantly reduced mitral regurgitation volume and improved heart failure symptoms in a patient with scleroderma myocarditis.
- Scleroderma myocarditis can present with heart failure and severe vFMR, which may be treatable with M-TEER.
- Combining M-TEER with immunosuppressive therapy led to hemodynamic stabilization in this case.

## Abstract

Systemic sclerosis presents with a variety of cardiac manifestations, while myocarditis is usually a rare finding. Furthermore, there are no reports on the use of mitral transcatheter edge-to-edge repair (M-TEER) for the treatment of severe ventricular functional mitral regurgitation (vFMR) secondary to scleroderma myocarditis.

A-79-year-old male was admitted to our hospital because of fever and fatigue. His physical examination revealed thickening of the fingertips’ skin, Raynaud phenomenon, and mild pedal oedema. Positive anti-centromere antibodies indicated a diagnosis of a limited cutaneous systemic sclerosis. He presented with symptoms of heart failure, and moderate to severe lymphocytic infiltration was evident in his endomyocardial biopsy. He responded well to medical therapy and was discharged. However, one month after hospital discharge, he was readmitted to our institution because of worsening heart failure. Transthoracic echocardiography showed a decrease in left ventricular systolic function and progression of left ventricular remodelling, which caused severe vFMR. Endomyocardial biopsy revealed decreased lymphocytic infiltration and mild myocardial interstitial fibrosis, indicative of scleroderma myocarditis. As he was unable to be weaned off inotropes, we performed M-TEER for severe vFMR, which led to a significant reduction in MR volume and improvement of heart failure symptoms. A week after procedure, immunosuppressive therapy was initiated and the patient was discharged home in stable condition.

Scleroderma myocarditis may manifest as heart failure with reduced ejection fraction with severe vFMR. Mitral transcatheter edge-to-edge repair for severe vFMR in the context of myocarditis can be one of the therapeutic options for haemodynamic stabilization.